

### **WHO Update**

Irena Prat and Josée Hansen World Health Organization Vancouver, 14-16 March 2017

### What's new?

- Prequalification of IVDs
  - New guidance documents
  - Post-market surveillance
  - Inspections
- Regulatory strengthening

## Impact of new WHO PQ documents and guidance

- Revised instructions Reportable changes to a prequalified IVD
  - Changes identified as reportable or non reportable c.f. first version (minor or substantial)
  - Provides greater clarity on what to report
  - > Increased compliance
- TGS 2 Establishing stability of an in vitro diagnostic for WHO Prequalification (draft)
  - Includes multiple examples of how to undertake the stability studies for IVDs required by existing standards (ISO, CLSI) in a WHO context
  - A number of manufacturers have had to request extensions to complete the studies




# Impact of new WHO PQ documents and guidance

- Technical Specification Series (TSS)
  - Clear requirements leading to improved processes at WHO
  - Timelines reduced for screening of dossiers
  - Greater consistency in assessments by external assessors
- TSS1 Human Immunodeficiency Virus (HIV) rapid diagnostic tests for professional use and/or self testing
  - Positive responses by industry to the detailed guidance on validation of HIV self tests
  - Manufacturers needing more time to complete the requested studies
- TSS 2 [Draft] Malaria rapid diagnostic tests
  - Many manufacturers of malaria rapid tests are not familiar with the compilation of dossiers and lack many of the requested studies
  - Several have withdrawn due to significant gaps in requirements



## WHO normative guidance on PMS

- Description of roles/ responsibilities of each stakeholder
  - Manufacturers, NRAs, NRLs (as testing laboratories), end-users, and WHO
- Template forms harmonized with MEDDEV and IMDRF
  - IVD complaint report, manufacturer investigation report, field safety corrective action report, lot testing data collection & report, field safety notice





## Status of WHO complaint monitoring activities

- 42 complaints submitted to WHO since November 2014
  - Mostly for WHO prequalified IVDs
  - Mostly in low resource settings, but for IVDs that are marketed worldwide
  - Typical FSCA were revised labelling and recall/destruction
- 2 falsified products reported, including one HIV IVD supplied to customer within EEA




## Global relevance of WHO PMS activities

Global Diagnostics Working Group will establish a subgroup on post-market surveillance

Exchange of information on complaints and coordinated action


Survey at recent WHO capacitybuilding workshop on PMS showed that most NRAs don't have capacity for PMS of IVDs Is there an unit within the national regulatory authority with responsibility for post-market surveillance of in vitro diagnostics?





## Inspections: April 2015 -2016


#### Number of sites





### Results: deficiencies

#### **Deficiencies**



World Health Organization 20 Avenue Appia

1211 Geneva 27, Switzerland

www.who.int/medical\_devices/



# Regulating Medical Devices

Bridging gaps on a global scale







## WHO Global Model Regulatory Framework for medical devices

- Approved by expert committees in October 2016
- Implementation plan:
  - Workshops at regional level
  - Pilot countries to implement the Model
  - Model will be used as basis for developing the Global Benchmarking tool for medical devices.

### New

- Essential diagnostics list
  - http://www.who.int/selection\_medicines/committees/e
     xpert/21/applications/essential\_in vitro\_diagnostics\_other/en/
- Upcoming: Third Global Forum on medical devices 10-12 May 2017, Geneva
  - http://www.who.int/medical\_devices/global\_forum/3rd\_gfmd/en/

## Thank you